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Abstract: Sickle cell disease is
the commonest single gene dis-
ease in Africa. Morbidity and
mortality from this disease has
remained unacceptably high in
Africa whereas there has been a
marked reduction in the burden of
this disease in the developed
countries. This reduction was not
achieved through the use of so-
phisticated care such as bone mar-
row transplant, but through the
adoption of a Comprehensive
Health Care Management proto-
col for sickle cell disease.  This
protocol of care emphasizes pre-
vention of crises through effective
management of the disease. In
Africa, where sickle cell disease is
prevalent, this strategy of care is
yet to be globally adopted.  In
2003, this protocol of care was
adopted at the University of Benin
Teaching Hospital, Nigeria and
this has contributed to the im-
proved clinical status of children
with sickle cell disease in the hos-
pital. The mortality rate among
children with sickle cell disease
has reduced to 1.3%, requirement
for recurrent blood transfusion has
reduced to about 2%, and their
nutritional status has improved:
75.9% have normal nutritional
status while 7% are actually over-
weight. The frequency of bone
pain crisis has reduced to about
one in every two years and some
of the patients have been crisis-
free for as long as five years. Hy-
droxyurea is not routinely used for
our patients so this cannot explain
the marked improvement recorded.
In conclusion, comprehensive
health care, adapted to our setting
is a very cheap and effective way
of managing sickle cell disease. It
can be utilized in all health facili-
ties for the care of children with
sickle cell disease and is capable
of reducing the morbidity and mor-
tality associated with the disease as
well as improving their quality of
life.
children with SCD. Therefore, alternative treatment mo-
dalities which are effective in reducing the morbidity
and mortality associated with SCD as well as improving
the quality of life in SCD are highly desirable.
The management of SCD continues to pose a challenge
in Africa. Not only does the populace have poor knowl-
edge of the disease,14 the healthcare providers may also
not be familiar with the current concepts in the manage-
ment of the disease. The management of SCD in most
health facilities in Africa largely addresses the complica-
tions of SCD rather than the disease itself hence, mor-
bidity and mortality in SCD has remained high. In some
developed countries, comprehensive health care was
adopted as the strategy for the management of SCD and
this has resulted in the reduction of mortality from 16-
30% to less than 1% in that setting.15-18 This method of
care, as practised in the developed countries, requires
the involvement of several professionals such as the
genetic counsellor, paediatric haematologist and the
social worker among others. This multi-disciplinary
approach offers a holistic form of care to children with
Introduction
Sickle cell disease (SCD) is the commonest single gene
disease in Africa.1 About 40 countries in Africa and at
least 23 countries of West and Central Africa carry the β
s gene.2 In Nigeria, 20-25% of the population are carri-
ers of the genetic abnormality,3 and about 3% of babies
are born with the disease4. The basic pathology in SCD
is the polymerization of haemoglobin following deoxy-
genation, a process that results in vaso-occlusion, which
is the hallmark of the disease5. This process results in
various forms of complications such as bone pains, ab-
dominal pain, cerebrovascular accidents and priapism,
which characterize the disease. In addition, children with
SCD are prone to various forms of infections as a result
of defective immunity arising from defective splenic
functions,6,7 functional abnormalities of white cells 8 as
well as abnormalities of the complement pathway.9 The
mortality rate in SCD has remained high in Africa. 10-13
Bone marrow and stem cells transplant offers the poten-
tial for clinical cure in SCD. This modality of treatment
is very expensive and thus, not available to a majority of
SCD and ideally should be the model of care. In Africa
and other developing countries where SCD is prevalent,
the form of care described above is not within reach due
to dearth of most of the required health professionals.
Therefore, there is a need to adapt this form of care for
the low-resource settings in Africa where SCD is preva-
lent. This model of care has been successfully adopted
in Cotonou, the Republic of Benin. This resulted in a
drastic reduction of morbidity and mortality associated
with SCD in the country. In recognition of this adapta-
tion, the World Health Organisation, at the meeting of
the Regional Committee for Africain June 2010, pro-
posed that by 2020, half of the 23-Member States with
high prevalence of SCD should have developed and
commenced the implementation of a clearly designed
National Sickle Cell Control programme within the con-
text of a National Health Strategic Plan. It is also ex-
pected that 25% of the countries in the African Region
should have adopted the concept of comprehensive
health care management by the year 2020. 19 This strat-
egy was adopted by the Sickle Cell Centre at the Repub-
lic of Benin in 1993 20 and the University of Benin, Be-
nin City, Nigeria in 2003. In Cotonou, the Republic of
Benin where this strategy of care is being utilized, the
mortality of SCD dropped to 15.5/ 10000, a value ten
times less than the overall Under-Five mortality ratein
that country. 21 In Italy where this strategy was also
adopted, the morbidities and mortality associated with
SCD have reduced. 22
In the last 13 years, the Paediatric Haematology Unit of
the University of Benin Teaching Hospital has man-
aged547 children with sickle cell anaemia (SCA) using
the new protocol. Twenty children with SCA died over
this period; the majority of the deaths occurred among
13 children referredfrom other facilities on account of
complications of SCA.  Seven children in the new proto-
col died; twofrom acute chest syndrome, one from liver
failure, one from sequestration crisis (died in a private
facility) and the rest from sepsis. In the last five years,
all the deaths among children in the programme oc-
curred at the Children Emergency Room before the Pae-
diatric Haematology Unit could have an input in their
care. The admission rate for sickle cell crises has re-
duced to an average of one in about two years with some
childrenbeing crises-free for fiveyears. The transfusion
rate has also reduced drastically to less than 2% and the
mortality rate amongst our cohort is 1.3% (7/547). Using
the Body Mass Index (BMI)-Z scores in a recent nutri-
tional survey of 187 children with SCD, the nutritional
status of the children in this programme was similar to
that of their peers, with a reduction in the prevalence
rate of severe malnutrition to less than 18%. Indeed,
75.9% had normal nutritional status while 7% were
overweight. With these achievements, it became neces-
sary to share this method of care so healthcare providers
in other parts of the country and beyond, can adopt same
and more children with SCD may benefit from its nu-
merous advantages.
Management of sickle cell disease
It is important to stress that the management of SCDis
not synonymous with the management of the complica-
tions of the disease. Patients with SCD only have
chronic anaemia as a constant feature of the disease.
While chronic anaemia is the only constant feature of
SCD, other morbidities associated with the disease are
actually complications of the disease.The aim of manag-
ing SCDincludes the prevention and early recognition of
the complications of the disease. These complications
are, usually, the causes of death in SCD.
The concept of Comprehensive Health Care manage-
ment of SCDis hinged on the following constituent ser-
vices which are provided by the clinician during clinic
visit:19
 Parental counselling and education.
 Education on the need for adequate nutrition.
 Education of the need for adequate hydration.
 Early identification of fever and its urgent treatment
 Early identification of a large spleen.
 Use of prophylactic medications like Penicillin V,
anti-malarial drugs, Folic acid and Vitamin C.
 Immunization againstinfections which are common
to children with SCD such asSalmonella, Hemophi-
lus influenza type b, Pneumococcus and Hepatitis B
virus infections.
 Need for regular hospital follow-up.
Parental counselling and education
The knowledge of how sickle cell disease is acquired
has remained very poor amongst Africans despite the
high prevalence of the disease in this area.14 Therefore,
marriage between carrier individuals persists without
inhibition.14 Usually, it is the presence of the disease in
an affected child that brings the carrier status of the par-
ents to fore. Only very few intending couples practice
pre-marital screening for SCD particularly where
churches insist on screening before marriages are con-
tracted.In situations where couples co-habit and where
marriages are contracted according to traditional prac-
tices,screening for SCD is usually not done. In counsel-
ling couples with a child who has sickle cell disease,
they are taught how the child acquired the disease and
the effects of the disease on the child are explained to
them to enhance a thorough understanding of the patho-
physiology of the disease. The aspect of education is
very important in an African setting where mothers are
usually blamed for the production of “bad children” or
witchcraft when families experience childhood deaths
attributed to SCD. In addition, the knowledge of the
patho-physiology of the disease helps parents to manage
the child with SCD better and comply with the protocol
of care.18The care of the children enrolled into this pro-
gramme is accomplished in the homes of the affected
families rather than in the hospitals, hence, the need for
parental education.
Adequate nutrition
Malnutrition is a common problem among African chil-
299
dren. A lot of African children are stunted due to poor
nutritional intake. In Nigeria, 41% of the general popu-
lation of children are stunted. 24 It is this same setting
that has the bulk of children withSCD.Specifically, SCD
poses a high nutritional burden on the affected children.
The disease is associated with a high metabolic rate be-
cause of the bone marrow hyperactivity.25,26 The life
span of the sickled red cell is 10-20 days instead of the
100-120 days for normal haemoglobin. This places a
high nutritional demand on the child with SCD. In addi-
tion, a child with SCD also requires the same nutrients
for his growth and development. This implies that chil-
dren with SCD on diet similar to that of healthy children
are at risk of failure to thrive in early childhood and
stunted grow with delayed secondary sexual characteris-
tics later in life. These children are usually thin with
asthenic build. With adequate nutrition, children with
SCD are able to achieve normal growth and develop-
ment as their peers with normal haemoglobin. The stig-
mata of the disease such as prognatism, skull bossing
and long thin extremities have been observed to disap-
pear with adequate nutrition. Therefore, caregivers are
advised to feed their children frequently with as much as
six to eight meals daily using nutritious diets. Non-
nutritious meals or snacks should be discouraged and the
parents are advised to ensure children go to school with
food instead of snacks.
Adequate hydration
Vaso-occlusive events occur frequently among children
with SCDbecause the sickled red cells cause hypervis-
cosity of the blood which results in sluggish blood flow.
Dehydration worsens this hyperviscosity and the latter
reduces the flow velocity and thus, increases the delay
time that is critical in polymer formation.5 Polymers are
responsible for vaso-occlusion which is the hallmark of
SCD. Most of the morbidities and mortality which char-
acterize SCD result from multiple organ damage follow-
ing recurrent vaso-occlusive events. Therefore, the pre-
vention of vaso-occlusive events is important in ensur-
ing not only the wellbeing of the SCD child but also the
prevention of chronic organ damage and early death.
Children with SCD are advised to drink 2-3L /m2 of
water daily. The child is advised to go about with water
in order to facilitate adequate water intake and good
hydration. Adequate hydration also enhances the urinary
excretion of bilirubin resulting from the chronic haemo-
lytic state in SCD. Children with SCD in our programme
remain crisis-freefor as long as two to five years follow-
ing adequate water intake. Hydroxyurea, an anti-sickling
drug, is not routinely used for the children with SCD
enrolled in the programme hence the use of this medica-
tion may not explain the observed improvements among
our cohorts.
Early identification and treatment of fever
Fever is regarded as an emergency in a child with SCD
as fever may be a flag sign for infections. Infections are
common causes of morbidities and mortality among
children with SCD since their immune functions are
usually poor.27 Caregivers should be taught how to de-
tect fever in children using a thermometer or by feel and
report to the hospital once the child with SCD is noticed
to the febrile. In most parts of Africa, this advice is very
pertinent as most caregivers patronize drug vendors for
medications when their children are ill. This contributes
to delay in seeking appropriate care for the child with
SCD. It is important to note that pneumococcal infec-
tions have a doubling rate of 30 minutes.28
Early identification of a large spleen
Splenic function among children with SCD is defective
as early as the sixth month of life. However, the most
life threatening splenic event in SCD is the sequestration
crisis.29This event results in the pooling of sickled red
cells in the spleen with a resultant severe anaemia and
severe hypovolaemia or shock.  This event can be fatal if
it is not promptly identified and appropriately managed
with blood transfusion.29 Caregivers should be taught
how to identify a large spleen in a child. In Africa, iden-
tifying a large spleen by caregivers is important asits
presence has been associated with anaemia and frequent
illness. In traditional parlance, scarification marks are
made over the abdomen to “treat the spleen”. A large
number of children with SCDin Nigeria have these
scarification marks on their anterior abdominal wall.
The caregivers should be taught how to detect a large
spleen in their children during bath. The caregivers are
advised to take the child to the hospital if they notice an
enlarged spleen for thorough evaluation especially to
check the packed cell volume.
Use of prophylactic medications
Drugs routinely given to children with SCD include Fo-
lic acid 5 mg daily, Vitamin C and malaria prophylaxis.
Folic acid therapy prevents megaloblastic crises as a
result of high red cell turnover, Vitamin C functions as
anti-oxidant because of the oxidant stress imposed by
the red cell hemolysis30 while malarial prophylaxis is
important for children in malaria-endemic region.17 Ma-
laria not only worsens the anaemia but is also a cause of
frequent morbidity. Penicillin V tablet is administered
for the prevention of pneumococcal infections.31, 32 For
children less than three years, Penicillin V 125 000 IU is
administered twice daily while the dose is doubled for
children aged between three and five  years. The drug is
used along with the pneumococcal vaccine.
Immunization for the child with SCD
Infection is the commonest cause of death in SCD chil-
dren, especially infections due to encapsulated organ-
isms.27,28,31,33-35 Therefore, vaccinations against Haemo-
philus influenza type b,36pneumoccocus37,38 and Salmo-
nella are essential in the care of children with
SCD.However, the routine immunization schedules in
most African countries do not include these vaccines.
Nigeria, for example, has just implemented the use of
the Haemophilus influenza type b and pneumococcal
vaccines for routine immunization. Salmonella vaccine
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is not included in the routine immunization schedule for
children in Nigeria.  These bacterial organisms have
been proven to be the major causes of infections in chil-
dren with SCD, hence, there is an urgent need to vacci-
nate these immune-compromised children to prevent
morbidities and mortality associated with infections.
These vaccines are routinely used for the children with
SCD enrolled into the programme at the University of
Benin Teaching Hospital, Benin City. Hepatitis B vac-
cine was only introduced 12 years ago in Nigeria, hence,
children with SCD who are older than 12 years must
have missed the vaccines. Therefore, children who are
older than 12 years and those aged less than 12 years but
who were not vaccinated should be tested for Hepatitis
B virus infection and the vaccine should be administered
if they are sero-negative.
Regular hospital follow up
For a disease that has lifelong implications, there is a
need for regular hospital follow up. In Africa, most pa-
tients with SCD do not attend follow-up care in the hos-
pital setting. Children are only brought for care when
they have crises. This attitude may be is detrimental to
the health of children with SCD because regular follow-
up hospital visits may ensure adequate growth and de-
velopment through growth monitoring and frequent edu-
cation. This allows for early identification and prompt
management of complications. This allows the child
with SCD to maintain good health.
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